Pfizer Operating Margin 2012-2026 | PFE
Current and historical operating margin for Pfizer (PFE) over the last 10 years. The current operating profit margin for Pfizer as of March 31, 2026 is 29.41%.
| Pfizer Operating Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Operating Income | Operating Margin |
| 2026-03-31 | $63.32B | $14.54B | 22.96% |
| 2025-12-31 | $62.58B | $14.24B | 22.76% |
| 2025-09-30 | $62.79B | $13.72B | 21.85% |
| 2025-06-30 | $63.83B | $14.83B | 23.23% |
| 2025-03-31 | $62.46B | $12.05B | 19.29% |
| 2024-12-31 | $63.63B | $12.41B | 19.51% |
| 2024-09-30 | $60.43B | $5.78B | 9.56% |
| 2024-06-30 | $56.22B | $-2.35B | -4.19% |
| 2024-03-31 | $55.95B | $-1.16B | -2.08% |
| 2023-12-31 | $59.55B | $1.28B | 2.15% |
| 2023-09-30 | $70.12B | $10.79B | 15.39% |
| 2023-06-30 | $79.27B | $22.91B | 28.90% |
| 2023-03-31 | $94.00B | $32.93B | 35.03% |
| 2022-12-31 | $101.18B | $35.79B | 35.37% |
| 2022-09-30 | $99.88B | $33.55B | 33.59% |
| 2022-06-30 | $101.28B | $30.76B | 30.37% |
| 2022-03-31 | $92.43B | $24.15B | 26.12% |
| 2021-12-31 | $81.29B | $19.43B | 23.91% |
| 2021-09-30 | $68.88B | $17.15B | 24.89% |
| 2021-06-30 | $55.12B | $13.45B | 24.39% |
| 2021-03-31 | $46.08B | $9.91B | 21.51% |
| 2020-12-31 | $41.65B | $8.25B | 19.81% |
| 2020-09-30 | $32.07B | $2.62B | 8.17% |
| 2020-06-30 | $34.47B | $3.13B | 9.08% |
| 2020-03-31 | $37.87B | $5.32B | 14.06% |
| 2019-12-31 | $40.91B | $6.71B | 16.40% |
| 2019-09-30 | $40.22B | $5.62B | 13.98% |
| 2019-06-30 | $40.84B | $6.43B | 15.74% |
| 2019-03-31 | $41.04B | $6.14B | 14.95% |
| 2018-12-31 | $40.83B | $5.67B | 13.89% |
| 2018-09-30 | $53.37B | $14.00B | 26.22% |
| 2018-06-30 | $53.24B | $13.90B | 26.10% |
| 2018-03-31 | $52.67B | $13.66B | 25.94% |
| 2017-12-31 | $52.55B | $13.72B | 26.11% |
| 2017-09-30 | $52.47B | $13.17B | 25.10% |
| 2017-06-30 | $52.35B | $12.53B | 23.93% |
| 2017-03-31 | $52.60B | $12.26B | 23.32% |
| 2016-12-31 | $52.82B | $12.15B | 22.99% |
| 2016-09-30 | $53.24B | $12.22B | 22.96% |
| 2016-06-30 | $52.29B | $12.56B | 24.02% |
| 2016-03-31 | $50.99B | $12.68B | 24.86% |
| 2015-12-31 | $48.85B | $11.82B | 24.20% |
| 2015-09-30 | $47.92B | $12.14B | 25.33% |
| 2015-06-30 | $48.20B | $12.46B | 25.85% |
| 2015-03-31 | $49.12B | $12.82B | 26.09% |
| 2014-12-31 | $49.61B | $13.25B | 26.71% |
| 2014-09-30 | $50.05B | $14.15B | 28.26% |
| 2014-06-30 | $50.33B | $14.45B | 28.71% |
| 2014-03-31 | $50.53B | $14.78B | 29.26% |
| 2013-12-31 | $51.58B | $15.18B | 29.44% |
| 2013-09-30 | $50.88B | $14.70B | 28.90% |
| 2013-06-30 | $51.19B | $14.46B | 28.25% |
| 2013-03-31 | $52.18B | $15.04B | 28.82% |
| 2012-12-31 | $54.66B | $15.26B | 27.93% |
| 2012-09-30 | $53.25B | $14.62B | 27.45% |
| 2012-06-30 | $56.90B | $14.96B | 26.29% |
| 2012-03-31 | $59.42B | $14.12B | 23.76% |
| 2011-12-31 | $61.04B | $13.97B | 22.88% |
| 2011-09-30 | $65.06B | $13.94B | 21.43% |
| 2011-06-30 | $64.44B | $13.62B | 21.13% |
| 2011-03-31 | $65.09B | $13.80B | 21.19% |
| 2010-12-31 | $65.17B | $13.41B | 20.58% |
| 2010-09-30 | $65.50B | $11.49B | 17.54% |
| 2010-06-30 | $61.13B | $11.85B | 19.39% |
| 2010-03-31 | $54.98B | $10.77B | 19.60% |
| 2009-12-31 | $49.27B | $10.96B | 22.24% |
| 2009-09-30 | $45.82B | $13.43B | 29.32% |
| 2009-06-30 | $46.17B | $12.75B | 27.61% |
| 2009-03-31 | $47.32B | $12.25B | 25.89% |
| 2008-12-31 | $48.30B | $11.73B | 24.28% |
| 2008-09-30 | $48.82B | $11.65B | 23.86% |
| 2008-06-30 | $48.84B | $8.58B | 17.57% |
| 2008-03-31 | $47.79B | $7.09B | 14.84% |
| 2007-12-31 | $48.42B | $7.52B | 15.53% |
| 2007-09-30 | $48.15B | $6.93B | 14.39% |
| 2007-06-30 | $48.44B | $10.17B | 20.99% |
| 2007-03-31 | $49.10B | $11.76B | 23.95% |
| 2006-12-31 | $48.37B | $12.12B | 25.06% |
| 2006-09-30 | $47.37B | $13.03B | 27.51% |
| 2006-06-30 | $46.35B | $11.27B | 24.32% |
| 2006-03-31 | $46.06B | $11.26B | 24.45% |
| 2005-12-31 | $47.41B | $11.20B | 23.62% |
| 2005-09-30 | $47.20B | $12.08B | 25.60% |
| 2005-06-30 | $48.77B | $14.46B | 29.64% |
| 2005-03-31 | $49.59B | $15.07B | 30.38% |
| 2004-12-31 | $48.99B | $14.21B | 29.00% |
| 2004-09-30 | $51.57B | $12.68B | 24.59% |
| 2004-06-30 | $51.09B | $10.82B | 21.17% |
| 2004-03-31 | $48.72B | $3.94B | 8.09% |
| 2003-12-31 | $44.74B | $4.26B | 9.51% |
| 2003-09-30 | $40.01B | $5.56B | 13.89% |
| 2003-06-30 | $35.66B | $6.14B | 17.22% |
| 2003-03-31 | $33.05B | $12.02B | 36.36% |
| 2002-12-31 | $32.29B | $11.59B | 35.89% |
| 2002-09-30 | $29.03B | $10.45B | 35.99% |
| 2002-06-30 | $28.86B | $10.24B | 35.49% |
| 2002-03-31 | $29.19B | $10.32B | 35.35% |
| 2001-12-31 | $29.02B | $9.89B | 34.07% |
| 2001-09-30 | $31.14B | $7.92B | 25.42% |
| 2001-06-30 | $30.47B | $6.92B | 22.72% |
| 2001-03-31 | $29.84B | $5.99B | 20.07% |
| 2000-12-31 | $29.41B | $3.74B | 12.71% |
| 2000-09-30 | $25.81B | $4.82B | 18.68% |
| 2000-06-30 | $21.99B | $3.42B | 15.56% |
| 2000-03-31 | $18.78B | $3.02B | 16.11% |
| 1999-12-31 | $15.54B | $3.89B | 25.01% |
| 1999-09-30 | $14.90B | $3.90B | 26.14% |
| 1999-06-30 | $14.90B | $4.52B | 30.36% |
| 1999-03-31 | $14.24B | $3.91B | 27.44% |
| 1998-12-31 | $13.35B | $3.41B | 25.51% |
| 1998-09-30 | $12.39B | $2.41B | 19.42% |
| 1998-06-30 | $11.71B | $1.87B | 15.93% |
| 1998-03-31 | $11.09B | $1.69B | 15.22% |
| 1997-12-31 | $10.74B | $1.58B | 14.72% |
| 1997-09-30 | $10.99B | $1.79B | 16.30% |
| 1997-06-30 | $11.14B | $2.18B | 19.59% |
| 1997-03-31 | $11.31B | $2.54B | 22.48% |
| 1996-12-31 | $11.31B | $2.80B | 24.80% |
| 1996-09-30 | $10.89B | $2.83B | 25.96% |
| 1996-06-30 | $10.63B | $2.68B | 25.25% |
| 1996-03-31 | $10.37B | $2.50B | 24.15% |
| 1995-12-31 | $10.02B | $2.30B | 22.94% |
| 1995-09-30 | $9.58B | $2.25B | 23.53% |
| 1995-06-30 | $9.11B | $2.07B | 22.71% |
| 1995-03-31 | $8.64B | $2.01B | 23.30% |
| 1994-12-31 | $8.28B | $1.97B | 23.83% |
| 1994-09-30 | $7.97B | $1.88B | 23.54% |
| 1994-06-30 | $7.77B | $1.82B | 23.39% |
| 1994-03-31 | $7.59B | $1.74B | 22.95% |
| 1993-12-31 | $7.48B | $1.67B | 22.27% |
| 1993-09-30 | $7.44B | $1.62B | 21.73% |
| 1993-06-30 | $7.39B | $1.57B | 21.26% |
| 1993-03-31 | $7.34B | $1.52B | 20.75% |
| 1992-12-31 | $7.23B | $1.44B | 19.96% |
| 1992-09-30 | $7.13B | $1.35B | 18.88% |
| 1992-06-30 | $7.08B | $1.32B | 18.61% |
| 1992-03-31 | $7.02B | $1.29B | 18.39% |
| 1991-12-31 | $6.95B | $1.25B | 18.04% |
| 1991-09-30 | $6.89B | $1.20B | 17.49% |
| 1991-06-30 | $6.76B | $1.16B | 17.17% |
| 1991-03-31 | $6.62B | $1.12B | 16.95% |
| 1990-12-31 | $6.41B | $1.05B | 16.45% |
| 1990-09-30 | $6.12B | $1.02B | 16.60% |
| 1990-06-30 | $5.91B | $0.98B | 16.60% |
| 1990-03-31 | $5.72B | $0.95B | 16.61% |
| 1989-12-31 | $5.67B | $0.97B | 17.07% |
| 1989-09-30 | $5.55B | $0.97B | 17.44% |
| 1989-06-30 | $5.49B | $0.97B | 17.69% |
| 1989-03-31 | $5.52B | $1.05B | 19.05% |
| 1988-12-31 | $5.39B | $1.01B | 18.77% |
| 1988-09-30 | $5.29B | $1.01B | 19.01% |
| 1988-06-30 | $5.21B | $0.99B | 19.03% |
| 1988-03-31 | $5.10B | $0.99B | 19.40% |
| 1987-12-31 | $4.92B | $0.94B | 19.11% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |